Joel Greenblatt's ABT Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 64,588 shares of Abbott Laboratories (ABT) worth $8.65 M, representing 0.04% of the portfolio. First purchased in 2015-Q1, this long-term strategic position has been held for 43 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in ABT, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2015, adding 1 M shares. Largest reduction occurred in Q4 2015, reducing 1.36 M shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Abbott Laboratories (ABT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Abbott Laboratories (ABT) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2015 | +41,573 | New Buy | 41,573 | $46.33 |
| Q2 2015 | +1 M | Add 2409.54% | 1.04 M | $49.08 |
| Q3 2015 | +411,996 | Add 39.49% | 1.46 M | $40.22 |
| Q4 2015 | -1.36 M | Reduce 93.21% | 98,838 | $44.91 |
| Q1 2016 | +763,024 | Add 771.99% | 861,862 | $41.83 |
| Q2 2016 | -731,808 | Reduce 84.91% | 130,054 | $39.31 |
| Q3 2016 | -130,054 | Sold Out | 130,054 | $39.31 |
| Q4 2016 | +1.01 M | New Buy | 1.01 M | $38.41 |
| Q1 2017 | -610,673 | Reduce 60.43% | 399,925 | $44.41 |
| Q2 2017 | -399,925 | Sold Out | 399,925 | $44.41 |
| Q3 2017 | +17,851 | New Buy | 17,851 | $53.39 |
| Q4 2017 | +839,632 | Add 4703.56% | 857,483 | $57.07 |
| Q1 2018 | -256,844 | Reduce 29.95% | 600,639 | $59.92 |
| Q2 2018 | -432,564 | Reduce 72.02% | 168,075 | $60.99 |
| Q3 2018 | -31,204 | Reduce 18.57% | 136,871 | $73.36 |
| Q4 2018 | +23,405 | Add 17.10% | 160,276 | $72.33 |
| Q1 2019 | +48,020 | Add 29.96% | 208,296 | $79.94 |
| Q2 2019 | -197,960 | Reduce 95.04% | 10,336 | $84.08 |
| Q3 2019 | -3,018 | Reduce 29.20% | 7,318 | $83.63 |
| Q4 2019 | +2,643 | Add 36.12% | 9,961 | $86.84 |
| Q1 2020 | +60,775 | Add 610.13% | 70,736 | $78.91 |
| Q2 2020 | +23,364 | Add 33.03% | 94,100 | $91.43 |
| Q3 2020 | -18,170 | Reduce 19.31% | 75,930 | $108.82 |
| Q4 2020 | -27,304 | Reduce 35.96% | 48,626 | $109.49 |
| Q1 2021 | +6,741 | Add 13.86% | 55,367 | $119.84 |
| Q2 2021 | +998 | Add 1.80% | 56,365 | $115.92 |
| Q3 2021 | +7,880 | Add 13.98% | 64,245 | $118.13 |
| Q4 2021 | -5,107 | Reduce 7.95% | 59,138 | $140.74 |
| Q1 2022 | +51,671 | Add 87.37% | 110,809 | $118.36 |
| Q2 2022 | +4,349 | Add 3.92% | 115,158 | $108.65 |
| Q3 2022 | -12,293 | Reduce 10.67% | 102,865 | $96.76 |
| Q4 2022 | -13,799 | Reduce 13.41% | 89,066 | $109.79 |
| Q1 2023 | -23,528 | Reduce 26.42% | 65,538 | $101.26 |
| Q2 2023 | -30,060 | Reduce 45.87% | 35,478 | $109.02 |
| Q3 2023 | -3,989 | Reduce 11.24% | 31,489 | $96.85 |
| Q4 2023 | -577 | Reduce 1.83% | 30,912 | $110.07 |
| Q1 2024 | +3,493 | Add 11.30% | 34,405 | $113.66 |
| Q2 2024 | +326 | Add 0.95% | 34,731 | $103.91 |
| Q3 2024 | +5,573 | Add 16.05% | 40,304 | $114.01 |
| Q4 2024 | -969 | Reduce 2.40% | 39,335 | $113.11 |
| Q1 2025 | +16,779 | Add 42.66% | 56,114 | $132.65 |
| Q2 2025 | +22,316 | Add 39.77% | 78,430 | $136.01 |
| Q3 2025 | -13,842 | Reduce 17.65% | 64,588 | $133.94 |
Joel Greenblatt's Abbott Laboratories Investment FAQs
Joel Greenblatt first purchased Abbott Laboratories (ABT) in Q1 2015, acquiring 41,573 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Abbott Laboratories (ABT) for 43 quarters since Q1 2015.
Joel Greenblatt's largest addition to Abbott Laboratories (ABT) was in Q4 2016, adding 1,010,598 shares worth $38.82 M.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 64,588 shares of Abbott Laboratories (ABT), valued at approximately $8.65 M.
As of the Q3 2025 filing, Abbott Laboratories (ABT) represents approximately 0.04% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Abbott Laboratories (ABT) was 1,455,289 shares, as reported at the end of Q3 2015.